|
|
|
Price: $0.2800
$0.01 
2.527%
|
| Day's High:
| $0.2899
| Week Perf:
| -16.62 %
|
| Day's Low: |
$ 0.26 |
30 Day Perf: |
27.27 % |
| Volume (M): |
1,392 |
52 Wk High: |
$ 3.49 |
| Volume (M$): |
$ 390 |
52 Wk Avg: |
$0.46 |
| Open: |
$0.26 |
52 Wk Low: |
$0.16 |
|
|
| Market Capitalization (Millions $) |
2 |
| Shares
Outstanding (Millions) |
6 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-5 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
0 |
N2off Inc
Company Address: HaPardes 134 (Meshek Sander) Neve Yarak 4994500
Company Phone Number: 468 9583 Stock Exchange / Ticker: NASDAQ NITO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| N2off Inc
As the first quarter of 2024 earnings season unfolds, N2off Inc's financial results have drawn significant attention from Wall Street investors. With a reported net shortfall of $-0.26 per share, the company's performance has seemingly improved when compared to the same period last year, but it failed to meet expectations set in the previous quarter. To better understand the impact of these figures, we will delve into the context surrounding N2off Inc's financial results.
Revenue Decline and Bi-Annual Comparison:
N2off Inc's revenue experienced a sharp decline of -63.779% in the first quarter of 2024, dropping to $0.04 million from $0.12 million during the same period a year ago. This significant decrease illustrates substantial challenges faced by the company in maintaining its revenue streams. Moreover, the sequential revenue decline of -58.582% from $0.11 million further emphasizes N2off Inc's ongoing struggle to generate sustainable revenue growth.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.97 $ |
| Revenues (TTM) |
0.04 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.43 $
|
| Book Value |
0.78 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.97 $
|
| Revenues (TTM) |
0.04 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.43 $
|
| Book Value |
0.78 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Pathogen Prevention |
|
 100 % |
of total Revenue |
| ISRAEL |
|
91.45 % |
of total Revenue |
| UNITED STATES |
|
8.55 % |
of total Revenue |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
